mRNA Vaccine Controversies and Accountability

This chapter examines the recent decision by the U.S. Department of Health and Human Services to halt new mRNA vaccine development, catalyzed by doubts over their efficacy. It features expert insights on the implications of funding cuts, safety concerns, and the influence of pharmaceutical advertising on consumer perceptions. The discussion emphasizes the need for transparency and accountability in vaccine research and deployment, urging a critical reevaluation of past health strategies post-COVID-19 pandemic.